Limits...
Placental fibroblast growth factor 21 is not altered in late-onset preeclampsia.

Dekker Nitert M, Scholz-Romero K, Kubala MH, McIntyre HD, Callaway LK, Barrett HL - Reprod. Biol. Endocrinol. (2015)

Bottom Line: Placental mRNA expression of the FGF receptors (1-4) and the co-receptor beta-Klotho was not different between the groups.There was no difference in the expression of the glucose transporters GLUT1, 3 or 4.PPAR-alpha but not PPAR-gamma expression was decreased in PE.

View Article: PubMed Central - PubMed

Affiliation: School of Medicine, The University of Queensland, Butterfield Street, Herston, 4029, QLD, Australia. m.dekker@uq.edu.au.

ABSTRACT

Background: Preeclampsia (PE) is associated with alterations of placental function. The incidence of PE is higher in insulin resistant states. Women with PE have high circulating levels of the metabolic regulator fibroblast growth factor 21 (FGF21). FGF21 is synthesized in the placenta. The aim of this study was to compare the expression of FGF21, its receptors, downstream targets and transcriptional regulators in placental tissue from pregnancies with and without late-onset PE. Circulating FGF21 in maternal and cord blood was also studied.

Methods: mRNA expression was determined by semi-quantitative real-time PCR and normalized for cellular composition in 17 women with and 20 without PE. Protein expression was quantified by Western Blot. FGF21 levels were measured by ELISA in maternal and cord serum of ten mother-baby dyads per condition.

Results: Placental FGF21 mRNA and protein expression were similar in PE compared with control. Placental mRNA expression of the FGF receptors (1-4) and the co-receptor beta-Klotho was not different between the groups. There was no difference in the expression of the glucose transporters GLUT1, 3 or 4. PPAR-alpha but not PPAR-gamma expression was decreased in PE. Maternal FGF21 serum levels were not significantly different in PE. FGF21 was detected in cord blood of 6 infants (4 PE, 2 controls) but was undetectable in 14 infants.

Conclusions: Late-onset PE is not associated with major changes to the expression of FGF21, its receptors or metabolic targets.

No MeSH data available.


Related in: MedlinePlus

Placental FGF receptors in PE. A) Placental mRNA expression of FGF receptor isoforms 1–4 and the co-factor β-klotho (KLB) in 20 control women (white boxes) and 17 women with PE (grey boxes). Boxes, median (IQR); whiskers 2.5-97.5% CI; *, P < 0.05. Correlations between placental mRNA expression of FGF21 and FGFR1 (B), FGFR2 (C), FGFR3 (D), FGFR4 (E) and KLB (F) including 20 women with and 17 women without PE.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4384232&req=5

Fig2: Placental FGF receptors in PE. A) Placental mRNA expression of FGF receptor isoforms 1–4 and the co-factor β-klotho (KLB) in 20 control women (white boxes) and 17 women with PE (grey boxes). Boxes, median (IQR); whiskers 2.5-97.5% CI; *, P < 0.05. Correlations between placental mRNA expression of FGF21 and FGFR1 (B), FGFR2 (C), FGFR3 (D), FGFR4 (E) and KLB (F) including 20 women with and 17 women without PE.

Mentions: FGF21 can bind to all four isoforms of the FGF receptor family with a preference for FGFR4 especially in the presence of the co-receptor β-klotho (KLB). In PE, placental expression of each of the FGFR isoforms was not different from control pregnancies (Figure 2A): FGFR1 mRNA expression in PE 0.45 (0.14-2.33) vs. control 0.56 (0.15-1.30), P = 0.99; FGFR2 PE 0.36 (0.15-3.21) vs. control 0.59 (0.22-1.52), P = 0.99; FGFR3 PE 0.48 (0.11-1.56) vs. control 0.61 (0.27-1.59), P = 0.99; and FGFR4 PE 0.19 (0.07-0.79) vs. control 0.58 (0.16-1.68), P = 0.99. Placental mRNA expression for the co-factor β-klotho was not significantly increased in PE (1.07 (0.28-15.31)) vs. control 0.26 (0.10-1.09), P = 0.13. However, FGF21 mRNA expression correlated significantly and positively with the expression of all FGFR isoforms (Figure 2B-E) as well as β-klotho (Figure 2F).Figure 2


Placental fibroblast growth factor 21 is not altered in late-onset preeclampsia.

Dekker Nitert M, Scholz-Romero K, Kubala MH, McIntyre HD, Callaway LK, Barrett HL - Reprod. Biol. Endocrinol. (2015)

Placental FGF receptors in PE. A) Placental mRNA expression of FGF receptor isoforms 1–4 and the co-factor β-klotho (KLB) in 20 control women (white boxes) and 17 women with PE (grey boxes). Boxes, median (IQR); whiskers 2.5-97.5% CI; *, P < 0.05. Correlations between placental mRNA expression of FGF21 and FGFR1 (B), FGFR2 (C), FGFR3 (D), FGFR4 (E) and KLB (F) including 20 women with and 17 women without PE.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4384232&req=5

Fig2: Placental FGF receptors in PE. A) Placental mRNA expression of FGF receptor isoforms 1–4 and the co-factor β-klotho (KLB) in 20 control women (white boxes) and 17 women with PE (grey boxes). Boxes, median (IQR); whiskers 2.5-97.5% CI; *, P < 0.05. Correlations between placental mRNA expression of FGF21 and FGFR1 (B), FGFR2 (C), FGFR3 (D), FGFR4 (E) and KLB (F) including 20 women with and 17 women without PE.
Mentions: FGF21 can bind to all four isoforms of the FGF receptor family with a preference for FGFR4 especially in the presence of the co-receptor β-klotho (KLB). In PE, placental expression of each of the FGFR isoforms was not different from control pregnancies (Figure 2A): FGFR1 mRNA expression in PE 0.45 (0.14-2.33) vs. control 0.56 (0.15-1.30), P = 0.99; FGFR2 PE 0.36 (0.15-3.21) vs. control 0.59 (0.22-1.52), P = 0.99; FGFR3 PE 0.48 (0.11-1.56) vs. control 0.61 (0.27-1.59), P = 0.99; and FGFR4 PE 0.19 (0.07-0.79) vs. control 0.58 (0.16-1.68), P = 0.99. Placental mRNA expression for the co-factor β-klotho was not significantly increased in PE (1.07 (0.28-15.31)) vs. control 0.26 (0.10-1.09), P = 0.13. However, FGF21 mRNA expression correlated significantly and positively with the expression of all FGFR isoforms (Figure 2B-E) as well as β-klotho (Figure 2F).Figure 2

Bottom Line: Placental mRNA expression of the FGF receptors (1-4) and the co-receptor beta-Klotho was not different between the groups.There was no difference in the expression of the glucose transporters GLUT1, 3 or 4.PPAR-alpha but not PPAR-gamma expression was decreased in PE.

View Article: PubMed Central - PubMed

Affiliation: School of Medicine, The University of Queensland, Butterfield Street, Herston, 4029, QLD, Australia. m.dekker@uq.edu.au.

ABSTRACT

Background: Preeclampsia (PE) is associated with alterations of placental function. The incidence of PE is higher in insulin resistant states. Women with PE have high circulating levels of the metabolic regulator fibroblast growth factor 21 (FGF21). FGF21 is synthesized in the placenta. The aim of this study was to compare the expression of FGF21, its receptors, downstream targets and transcriptional regulators in placental tissue from pregnancies with and without late-onset PE. Circulating FGF21 in maternal and cord blood was also studied.

Methods: mRNA expression was determined by semi-quantitative real-time PCR and normalized for cellular composition in 17 women with and 20 without PE. Protein expression was quantified by Western Blot. FGF21 levels were measured by ELISA in maternal and cord serum of ten mother-baby dyads per condition.

Results: Placental FGF21 mRNA and protein expression were similar in PE compared with control. Placental mRNA expression of the FGF receptors (1-4) and the co-receptor beta-Klotho was not different between the groups. There was no difference in the expression of the glucose transporters GLUT1, 3 or 4. PPAR-alpha but not PPAR-gamma expression was decreased in PE. Maternal FGF21 serum levels were not significantly different in PE. FGF21 was detected in cord blood of 6 infants (4 PE, 2 controls) but was undetectable in 14 infants.

Conclusions: Late-onset PE is not associated with major changes to the expression of FGF21, its receptors or metabolic targets.

No MeSH data available.


Related in: MedlinePlus